ArticleHealth science reports2026
Advancements and Applications of Focused Assessed Transthoracic Echocardiography: A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Focused Assessed Transthoracic Echocardiography (FATE), developed by Dr. Erik Sloth in 1989, has become a key ultrasound technique for rapid bedside assessment of cardiac function. Its non-invasive nature, real-time imaging, and portability make it ideal for facilitating swift clinical decisions across various specialties. This review aims to explore the evolution of FATE, evaluate its current clinical applications, and discuss prospects, with a focus on training protocols, image interpretation, and the incorporation of emerging technologies. Methods: A narrative review of the literature was conducted, examining studies and guidelines related to the development, methodology, and implementation of the FATE protocol. Emphasis was placed on evidence regarding standard imaging views, training practices, and the integration of new technologies in clinical settings. Results: The FATE protocol utilizes standard echocardiographic views to enable the rapid detection of critical cardiac conditions such as cardiac tamponade, valvular dysfunction, and left ventricular failure. Its ease of use and effectiveness have led to widespread adoption in diverse settings, including resource-limited environments and by non-cardiologists. The review highlights improvements in training and image acquisition techniques while also noting challenges such as operator variability and the need for ongoing quality assurance. Emerging technologies, notably artificial intelligence and handheld ultrasound devices are beginning to expand FATE's diagnostic capabilities. Conclusion: FATE is a versatile and effective tool for rapid cardiac assessment that continues to evolve with advancements in technology and training. Addressing challenges such as operator variability will be essential for maximizing its clinical utility. Future research should focus on refining these aspects to further enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.